Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;1344(1):66-77.
doi: 10.1111/nyas.12718. Epub 2015 Feb 27.

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

Chadi G Abdallah  1 , Lynnette A Averill, John H Krystal
Affiliations
Review

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

Chadi G Abdallah et al. Ann N Y Acad Sci. 2015 May.

Abstract

The discovery of ketamine's rapid and robust antidepressant effects opened a window into a new generation of antidepressants. Multiple controlled trials and open-label studies have demonstrated these effects across a variety of patient populations known to often achieve little to no response from traditional antidepressants. Ketamine has been generally well tolerated across patient groups, with transient mild-to-moderate adverse effects during infusion. However, the optimal dosing and route of administration and the safety of chronic treatment are not fully known. This review summarizes the clinical effects of ketamine and its neurobiological underpinnings and mechanisms of action, which may provide insight into the neurobiology of depression, relevant biomarkers, and treatment _targets. Moreover, we offer suggestions for future research that may continue to advance the field forward and ultimately improve the psychopharmacologic interventions available for those individuals struggling with depressive and trauma-related disorders.

Keywords: antidepressant; depression; ketamine; neurobiology; treatment mechanisms.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

Dr. Averill declares no conflicts of interest.

Figures

Figure 1
Figure 1
Ketamine administration and time course. (A) Comprehensive screening and evaluation; (B) ketamine 0.5 mg/kg infused over 40 min; (C) immediate antidepressant effect; and (D) rapid antidepressant effects sustained for up to 28 days after a single ketamine infusion.
Figure 2
Figure 2
Mechanisms underlying the rapid andidepressant effects of ketamine. Changes in GluR1 appear to be region specific, with evidence for increased GluR1 in the medial prefrontal cortex but not the hippocampus. Abbreviations: ADE, antidepressant-like effects; NMDA-R, N-methyl-D-aspartate glutamate receptor; AMPA-R, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GluR1, R1 subunit of AMPA-R; eEF2k, eukaryotic elongation factor 2 kinase; BDNF, brain-derived neurotrophic factor; pmTOR, mammalian _target of rapamycin; GSK3, glycogen synthase kinase 3. ⊕, enhance/stimulate; ⊖, inhibit/reduce; ⊘, blockade.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Collins PY, et al. Grand challenges in global mental health. Nature. 2011;475:27–30. - PMC - PubMed
    1. Kessler RC, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA : the journal of the American Medical Association. 2003;289:3095–3105. - PubMed
    1. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. The American journal of psychiatry. 2006;163:1905–1917. - PubMed
    1. Katz MM, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2004;29:566–579. - PubMed
    1. Gaynes BN, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatric services (Washington, D.C.) 2009;60:1439–1445. - PubMed

Publication types

MeSH terms

  NODES
admin 4
Association 1
Project 1
twitter 2